Talk Radioisotopes: Going Nuclear on Cancer
Talk Radioisotopes: Going Nuclear on Cancer
Podcast Description
Radioisotopes are revolutionizing how cancers are detected and treated. But how do they work? And where is this field headed?
Whether you’re a healthcare professional, researcher, pharma exec, or industry analyst, this podcast is a go-to resource for the rapidly evolving radiopharmaceuticals landscape.
Welcome to Talk Radioisotopes: Going Nuclear on Cancer. We’ll take a look at the latest insights, trends and developments working to change patient outcomes and supply the fight against cancer.
Join host Scott Larrivee and experts from across the industry, as they break down the science, shed light on real-world opportunities, and take a peek behind the curtain at the people, companies, and programs driving innovation in nuclear medicine. This is Talk Radioisotopes: Going Nuclear on Cancer.
Brought to you by the team at Nusano.
Podcast Insights
Content Themes
The podcast centers on the evolving field of radiopharmaceuticals, covering essential topics such as targeted radiotherapies, regulatory challenges, and isotope supply chains. For example, episodes may delve into the implications of new isotopes for personalized cancer treatments or the impact of pharmaceutical companies entering the market.
Radioisotopes are revolutionizing how cancers are detected and treated. But how do they work? And where is this field headed?
Whether you’re a healthcare professional, researcher, pharma exec, or industry analyst, this podcast is a go-to resource for the rapidly evolving radiopharmaceuticals landscape.
Welcome to Talk Radioisotopes: Going Nuclear on Cancer. We’ll take a look at the latest insights, trends and developments working to change patient outcomes and supply the fight against cancer.
Join host Scott Larrivee and experts from across the industry, as they break down the science, shed light on real-world opportunities, and take a peek behind the curtain at the people, companies, and programs driving innovation in nuclear medicine. This is Talk Radioisotopes: Going Nuclear on Cancer.
Brought to you by the team at Nusano.
In this episode of Talk Radioisotopes, host Scott Ravi sits down with Sigal Kalmanson Cusnir, CEO and Co-Founder of Starget Pharma, an early-stage company at the forefront of precision oncology. Starget is redefining the way radiopharmaceuticals are discovered and developed by merging AI technology with decades of expertise in peptide chemistry.
Sigal shares how Starget’s proprietary backbone cyclization technology and in silico AI models enable the rapid development of metabolically stable and highly specific radioligands for hard-to-treat cancers. She also explains the company’s unique platform approach, which optimizes isotopes, chelators, and ligands for targeted cancer therapies, all in accelerated timelines.
Listeners will learn about Starget’s innovative drug discovery pipeline, the company’s ambitions to enter clinical trials, and the broader implications for the future of radiopharmaceuticals. This episode is a must-listen for biotech professionals, oncology researchers, and investors tracking the next wave of AI-powered drug development.
——–
Time Stamps:
- *(01:48) The Science Behind Smart Targeted Radioligands
- *(04:02) AI and Peptide Radioligand Discovery
- *(06:31) Understanding Starget Pharma’s Product Pipeline
- *(11:26) Emerging Isotopes and Future Prospects
- *(13:10) Sigal’s Advice for the Early Stage Companies
- *(19:35) Sigal’s Magic Wand
——–
‘Talk Radioisotopes: Going Nuclear on Cancer’ is brought to you by Nusano, a physics company whose breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. Find out more at Nusano.com.
——–
Links:
——-
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.